Development of targeted medical care (simultaneous diagnostic imaging and therapy) for pathogenic angiogenesis using fibrinolytic metabolites
Project/Area Number |
23390151
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | Okayama University |
Principal Investigator |
MATSUURA Eiji 岡山大学, 医歯(薬)学総合研究科, 教授 (20181688)
|
Project Period (FY) |
2011-11-18 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2012: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
Keywords | 血管新生 / ベータ2-グリコプロテインI / 抗血管新生剤 / B2GPI-ドメインI / nicked B2GPI / PETイメージング / 質量分析 / DDSキャリア / beta2 glycoprotein I / B2GPI-DI / VEGF / β2GPI / nicked-β2GPI / β2GPI-DI / DOTA修飾 / VEGF受容体 / MALDI-TOF-MS / β2-グリコプロテインI(β2GPI) / β2GPI-DV / nicked DV / 抗血管新生 / マイクロキャリア / 動脈硬化 / Theranostics |
Research Abstract |
By the cytostatic activity test and angiogenesis imaging analysis with human umbilical vein endothelial cells, we confirmed that DI of beta2-glycoprotein I (B2GPI) revealed dose- and time-dependent cytostatic and anti-angiogenesis activity. 64Cu-labeled DI and 64Cu-labeled B2GPI were prepared and used for PET/CT imaging of tumor-bearing mice. DI showed high tumor/blood ratio. 64Cu-labeled and B2GPI-bound liposomes were prepared as an experimental model of the Theranostics (simultaneous diagnostic imaging and therapy) technology.
|
Report
(4 results)
Research Products
(20 results)